|Bid||134.84 x 1000|
|Ask||150.00 x 900|
|Day's Range||145.02 - 147.00|
|52 Week Range||96.42 - 164.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||173.86|
Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential HENDERSON, NV / ACCESSWIRE / ...
Although 30 states have legalized cannabis in some capacity, the federal scheduling of pot is a major headache for businesses and medical patients.
Despite generally being a voice of opposition, seniors using medical cannabis for pain relief revealed intriguing results in a new survey.
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent. The successful trial takes the company one step closer to bringing the drug to the market, and comes close on the heels of regulatory approval for GW Pharmaceuticals Plc's cannabis-based treatment for the same form of epilepsy. Current treatment options for Dravet syndrome, which affects an estimated 20,000 patients in the United States, are limited to a combination of seizure medication and drugs to prevent emergencies.
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...
The U.S. Food and Drug Administration (FDA) last week made history: By giving approval for U.K.-based GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) application to market Epidiolex (to medically treat severe forms of epilepsy), it marked the FDA's groundbreaking admission that cannabis has medical value. For now, Epidiolex itself remains illegal for sale, pending the DEA's scheduling decision (likely as Schedule IV), due by September 23.
The FDA last week approved UK-based GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Epidiolex, a "pure plant-derived CBD" extract shown to drastically reduce seizures in children with epileptic ...
People vouching for marijuana legalization have been celebrating the recent green flag by the Food & Drug Administration (FDA) for the cannabis-based drug, Epidiolex. GW Pharmaceuticals (NASDAQ: GWPH), a London headquartered company is producing a drug for the treatment of epilepsy that uses cannabidiol, specifically for people suffering from Lennox-Gastaut and Dravet syndromes. Here we use TipRanks data to take a closer look at what Wall Street’s top analysts see in store for this volatile stock.
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). Albeit modestly, healthcare is one of the four sectors higher YTD, and biotechnology stocks are a big reason.
Th U.S. Food and Drug Administration (FDA) approved Epidiolex June 25, a CBD medicine developed by GW Pharmaceuticals (NASDAQ:GWPH) that treats two rare forms of epilepsy. The adage about buying on rumor and selling on news definitely hit GWPH stock as it’s lost almost 10% of its value in the days following the historic announcement. “This is the first FDA-approved drug that contains a purified drug substance derived from marijuana,” stated the FDA’s June 25 press release.
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, ...
GW Pharmaceuticals Plc grows about 20 tons of cannabis annually at greenhouses the size of football fields in an undisclosed corner of the English countryside. The plants, genetically modified to remove the psychoactive properties, are used to produce Epidiolex, a prescription drug for children with severe epilepsy. The U.S. Food and Drug Administration approved the treatment on June 25, making it the first prescription medicine derived from cannabis permitted to be sold in the U.S.